Edition:
United Kingdom

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

2.91USD
19 Oct 2018
Change (% chg)

$0.01 (+0.34%)
Prev Close
$2.90
Open
$2.91
Day's High
$2.91
Day's Low
$2.91
Volume
25
Avg. Vol
3,676
52-wk High
$6.64
52-wk Low
$2.28

Latest Key Developments (Source: Significant Developments)

Kazia Therapeutics Enters Clinical Collaboration With Dana-Farber Cancer Institute
Sunday, 21 Oct 2018 

Oct 22 (Reuters) - Kazia Therapeutics Ltd ::ENTERS COLLABORATION WITH DANA-FARBER CANCER INSTITUTE TO INVESTIGATE POTENTIAL USE OF NEW DRUG, GDC-0084 IN BREAST CANCER.  Full Article

Kazia Therapeutics Says To Divest A Research Program To Trobio Therapeutics Pty Ltd
Friday, 13 Jul 2018 

July 13 (Reuters) - Kazia Therapeutics Ltd ::TO DIVEST A RESEARCH PROGRAM TO TROBIO THERAPEUTICS PTY LTD .NEGOTIATED DIVESTMENT OF A RESEARCH PROGRAM TO TROBIO THERAPEUTICS PTY LTD, TO TAKE A 12% STAKE IN TROBIO.  Full Article

Kazia Therapeutics And Noxopharm Announce Collaboration
Tuesday, 26 Dec 2017 

Dec 27 (Reuters) - Noxopharm Ltd ::KAZIA THERAPEUTICS AND NOXOPHARM LIMITED ANNOUNCE COLLABORATION TO SUPPORT DEVELOPMENT OF NOXOPHARM LEAD PROGRAM, NOX66..  Full Article

Novogen ‍enters into deal to license & assign preclinical assets
Sunday, 12 Nov 2017 

Nov 13 (Reuters) - Novogen Ltd ::‍Entered into agreement to license & assign certain preclinical assets to Heaton-Brown Life Sciences​.‍Under terms of deal, co to receive 10 percent of equity in Heaton-Brown Life Sciences.  Full Article

Novogen terminates ATM-3507 preclinical development program
Wednesday, 5 Apr 2017 

Novogen Ltd : Novogen terminates ATM-3507 preclinical development program . Decision to terminate development of atm-3507 does not affect 'next-generation atm' program . Novogen anticipates significant future cost savings associated with termination . A reduction in headcount will be implemented, and other employees will be reallocated to new responsibilities . Atm-3507 (anisina) will not be progressed into clinical trials due to "unfavourable balance of preclinical activity relative to emerging toxicology findings" .Recently-announced crc-p grant for next-generation atm program is unaffected by the decision.  Full Article